GH Research (GHRS) Share-based Compensation (2021 - 2025)
GH Research (GHRS) recorded quarterly Share-based Compensation of $2.7 million in Q4 2025, up 13.8% quarter-over-quarter from $2.3 million in Q3 2025, and up 249.93% on a YoY basis from $759000.0 in Q4 2024.
GH Research (GHRS) Share-based Compensation (2021 - 2025) Analysis & Trends
GH Research's Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.7 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 249.93% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $8.5 million (up 626.22% YoY), while the FY2025 annual figure was $13.1 million, up 167.72% from the prior year.
- Share-based Compensation was $2.7 million for Q4 2025 at GH Research, up from $2.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.7 million in Q4 2025 to a low of -$138000.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $779388.9 across 5 years, with a median of $477000.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 130.6% in 2024, then soared 1461.59% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $235000.0 in 2021, then jumped by 107.66% to $488000.0 in 2022, then soared by 33.4% to $651000.0 in 2023, then increased by 16.59% to $759000.0 in 2024, then jumped by 249.93% to $2.7 million in 2025.
- The last three Share-based Compensation figures came in at $2.7 million (Q4 2025), $2.3 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 26.47 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.66 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 2.33 Mn |
| Sep 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 1.88 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 759,000.00 |
| Dec 31, 2024 | 759,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 651,000.00 |
| Dec 31, 2023 | 651,000.00 |
| Sep 30, 2023 | 647,000.00 |
| Sep 30, 2023 | 647,000.00 |